# LigoCyte Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ligocyte-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Bozeman, US
- Website: www.ligocyte.com
- Total disclosed funding: $30M
- Latest round: Series D (Jun 28, 2012)
- Investors on record: 7

## About

LigoCyte Pharmaceuticals Inc. is focused on delivering innovative biotechnology solutions, particularly in the field of vaccines and therapeutics aimed at infectious diseases and immune-related conditions.LigoCyte Pharmaceuticals Inc. is engaged in developing advanced biotechnology solutions and specializes in innovative vaccine platforms. The company is headquartered in Bozeman, US. The firm has raised a total amount of USD 2.00 mn in its latest funding round, which was a Series D round completed on June 28, 2012, with investments from Novartis Venture Fund, Forward Ventures, and F-Prime Capital. The latest funding values the company at USD 34.845 mn post-money. The founder's history is not detailed in the available information.LigoCyte Pharmaceuticals Inc. specializes in the development of advanced biotechnology solutions, primarily focusing on novel therapeutic and diagnostic products. Their core offerings include innovative vaccine platforms designed to address various infectious diseases and immune-related conditions, leveraging proprietary technologies that enhance efficacy and safety profiles. The company aims to resolve critical challenges in healthcare by providing vaccines that are effective and scalable for mass production, thereby improving accessibility for diverse populations. These products target healthcare providers, pharmaceutical companies, and research institutions across North America and Europe, with expanding interests in the Asia-Pacific region. The introduction of their flagship vaccine technology marks a significant milestone, with initial products launched in recent years aimed at high-priority health concerns.LigoCyte Pharmaceuticals Inc. operates on a revenue model that primarily hinges on strategic partnerships and collaborations with healthcare institutions and research organizations. The company engages in B2B transactions, providing its innovative vaccine solutions through direct contracts with healthcare providers and pharmaceutical companies. Revenue streams are generated through fixed-term agreements and milestone-based payments aligned with product development stages and successful deployment of their vaccine platforms. Pricing structures for their products are established through negotiations with partners, often reflecting the complexity and uniqueness of the technologies involved. This transactional approach promotes sustained engagement with clients while fostering a collaborative environment conducive to continued innovation and development in the biopharmaceutical space.LigoCyte Pharmaceuticals Inc. plans to use the USD 2.00 mn raised in the Series D funding to support the development of upcoming vaccine products aimed at addressing infectious diseases and immune conditions. The company is targeting the Asia-Pacific region for expansion, with plans to enter this market by 2023. The recent funding will facilitate the enhancement of their vaccine platforms and accelerate efforts to meet health needs in various geographic areas.

## Funding rounds

- Series D, Jun 28, 2012, $2M — Forward Ventures, Novartis Venture Fund, F-Prime Capital
- Series C, Mar 18, 2008, $28M — Athenian Venture Partners, Forward Ventures, Novartis Venture Fund, MC Life Science Ventures, F-Prime Capital, Icon Ventures, MedImmune Ventures

## Investors

- Athenian Venture Partners (https://capitalatlas.ai/funds/athenian-venture-partners) — Series C
- Forward Ventures (https://capitalatlas.ai/funds/forward-ventures) — Series C, Series D
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series C, Series D
- MC Life Science Ventures — Series C
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series C, Series D
- Icon Ventures (https://capitalatlas.ai/funds/icon-ventures) — Series C
- MedImmune Ventures (https://capitalatlas.ai/funds/medimmune-ventures) — Series C